HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

RP 58802B, a long-acting beta 2-adrenoceptor agonist: assessment of antiasthma activity in the guinea-pig in vivo.

Abstract
We have examined the protective actions of RP 58802B, a novel beta 2-adrenoceptor agonist, administered by the inhaled and oral routes in the anaesthetized and conscious guinea-pig against bronchospasm induced by histamine or antigen (ovalbumin). We have also examined the effects of RP 58802B on airway reactivity and inflammatory cell infiltration in platelet-activating factor (PAF) (aerosol)-induced bronchial hyperreactivity and on PAF (tracheal instillation)-induced microvascular leakage in the guinea-pig. Nebulized RP 58802B produced a rapid onset and long lasting inhibition of histamine-induced bronchospasm in the anaesthetized guinea-pig (EC50 = 3.2 +/- 0.9 micrograms/ml; duration greater than 90 min). Given orally, RP 58802B (5 mg/kg, 60 min before challenge) produced a greater than three-fold shift to the right of the dose-response curve and depressed the maximum response to histamine by 39 +/- 11%. Increasing the concentration to 25 mg/kg had no futher effect. Similar protection was still seen 4 h after oral dosing. In conscious guinea-pigs, RP 58802B (5 or 25 mg/kg, p.o. 60 min before challenge) significantly attenuated antigen-induced dyspnoea with the time to severe dyspnoea increasing from 170 +/- 32 to 325 +/- 32 s at the higher dose of drug. RP 58802B (10 or 25 mg/kg, p.o. 60 min before exposure to PAF) prevented the development of bronchial hyperreactivity. Although PAF-induced bronchial hyperreactivity was not accompanied by an increase in the number of pulmonary eosinophils, RP 58802B (25 mg/kg p.o.) reduced the numbers of eosinophils recovered by lavage. RP 58802B (10 mg/kg p.o.) significantly inhibited PAF-induced microvascular leakage into guinea-pig lung. These data suggest that RP 58802B, in addition to being a potent and long acting bronchodilator, may have a prophylactic role in preventing bronchial hyperreactivity and in reducing plasma exudation into the lungs.
AuthorsS L Underwood, S A Lewis, D Raeburn
JournalPulmonary pharmacology (Pulm Pharmacol) Vol. 5 Issue 3 Pg. 203-12 (Sep 1992) ISSN: 0952-0600 [Print] England
PMID1280178 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Adrenergic beta-Agonists
  • Antigens
  • Benzimidazoles
  • Dextrans
  • Ethanolamines
  • Platelet Activating Factor
  • fluorescein isothiocyanate dextran
  • Histamine
  • RP 58802B
  • Fluorescein-5-isothiocyanate
  • Albuterol
Topics
  • Administration, Inhalation
  • Administration, Oral
  • Adrenergic beta-Agonists (pharmacology)
  • Albuterol (pharmacology)
  • Anesthesia
  • Animals
  • Antigens (administration & dosage)
  • Asthma (drug therapy, physiopathology)
  • Benzimidazoles (pharmacology)
  • Bronchi (drug effects, metabolism)
  • Bronchial Hyperreactivity (chemically induced, drug therapy)
  • Bronchoalveolar Lavage Fluid (metabolism)
  • Bronchoconstriction (drug effects, physiology)
  • Dextrans (pharmacokinetics)
  • Ethanolamines (pharmacology)
  • Fluorescein-5-isothiocyanate (pharmacokinetics)
  • Guinea Pigs
  • Histamine (pharmacology)
  • Male
  • Platelet Activating Factor (pharmacology)
  • Time Factors
  • Trachea (drug effects, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: